Supplementary Figure 1 from Sphingosine-1-Phosphate Produced by Sphingosine Kinase 1 Promotes Breast Cancer Progression by Stimulating Angiogenesis and Lymphangiogenesis

Nagahashi, Masayuki; Ramachandran, Subramaniam; Kim, Eugene Y.; Allegood, Jeremy C.; Rashid, Omar M.; Yamada, Akimitsu; Zhao, Renping; Milstien, Sheldon; Zhou, Huiping; Spiegel, Sarah; Takabe, Kazuaki

doi:10.1158/0008-5472.22392216.v1

Supplementary Figure 1 from Sphingosine-1-Phosphate Produced by Sphingosine Kinase 1 Promotes Breast Cancer Progression by Stimulating Angiogenesis and Lymphangiogenesis

journal contribution

posted on 2023-03-30, 21:05 authored by Masayuki Nagahashi, Subramaniam Ramachandran, Eugene Y. Kim, Jeremy C. Allegood, Omar M. Rashid, Akimitsu Yamada, Renping Zhao, Sheldon Milstien, Huiping Zhou, Sarah Spiegel, Kazuaki Takabe

PDF file - 763K, Circulating levels of SK1-I and S1P in plasma from na�ve BALB/c mice. Mice were treated with SK1-I (20 mg/kg) i.p. and plasma samples were taken at the indicated time point (n = 3). The levels of SK1-I (A) and S1P (B) were determined by LC-ESI-MS/MS, and means � SD are shown. *, P < 0.05 as compared to 0 hour time point.

History

ARTICLE ABSTRACT

Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid mediator that promotes breast cancer progression by diverse mechanisms that remain somewhat unclear. Here we report pharmacologic evidence of a critical role for sphingosine kinase 1 (SphK1) in producing S1P and mediating tumor-induced hemangiogenesis and lymphangiogenesis in a murine model of breast cancer metastasis. S1P levels increased both in the tumor and the circulation. In agreement, serum S1P levels were significantly elevated in stage IIIA human breast cancer patients, compared with age/ethnicity-matched healthy volunteers. However, treatment with the specific SphK1 inhibitor SK1-I suppressed S1P levels, reduced metastases to lymph nodes and lungs, and decreased overall tumor burden of our murine model. Both S1P and angiopoietin 2 (Ang2) stimulated hemangiogenesis and lymphangiogenesis in vitro, whereas SK1-I inhibited each process. We quantified both processes in vivo from the same specimen by combining directed in vivo angiogenesis assays with fluorescence-activated cell sorting, thereby confirming the results obtained in vitro. Notably, SK1-I decreased both processes not only at the primary tumor but also in lymph nodes, with peritumoral lymphatic vessel density reduced in SK1-I–treated animals. Taken together, our findings show that SphK1-produced S1P is a crucial mediator of breast cancer–induced hemangiogenesis and lymphangiogenesis. Our results implicate SphK1 along with S1P as therapeutic targets in breast cancer. Cancer Res; 72(3); 726–35. ©2012 AACR.